the term of metabolous syndrome is used to relate a mix of metabolic disorders that all together grow the risk of type 2 diabetes mellitus t2dm and cardiovascular diseases. the part of metabolous syndrome are including the existence of centralobesity dyslipidemia glucose intolerance and hypertension the worldwide prevalence of metabolic syndrome is variable ranging from 10% to 84% depending on geographical origins and composition of the studied population metabolic syndrome prevalence has been increased substantially in the last two decades which should be a priority for public health it is estimated that people with metabolic syndrome are twice as likely to die and three times as likely to have a heart attack or stroke compared with people without thesyndrome moreover compared with persons without metabolic syndrome those with the syndrome have an approximately 5-foldincrease in diabetes risk. however when metabolic syndrome combines with prediabetes the risk is increased even more indeed two clinical constructs for identifying individuals at high risk of developing type 2 diabetes are metabolic syndrome and prediabetes. thus effective treatment of these at-risk individuals is imperative for the prevention of type 2 diabetes to date the intestinal microbiota has been interested in its equivocal impact on health and is an emerging investigative field the connection between metabolic syndrome and gut microbiota is now acknowledged and some of the therapeutic strategies have been proposed to improve the composition of the gut microflora in order to promote optimal metabolic health current investigations suggest that manipulation of the gut microbiota by probiotics prebiotics and synbiotics could be a promising approach for the management of metabolic syndrome